I look for situations where the risk-reward is skewed heavily in one direction. Amgen (AMGN) just set up that exact scenario with their Q3 earnings. Strong revenue growth, broad product momentum, attractive valuation, and a market that’s already priced in the worst-case scenario. When you find quality trading cheaply because of overblown fears, you’ve found […]
Category Archives: Biotech Letter
Mad Hedge Biotech and Healthcare Letter November 13, 2025 Fiat Lux Featured Trade: (YOUR REMINDER THAT MARKETS PANIC and PIPELINES DON’T) (ABBV)
AbbVie (ABBV) is back in the headlines, and for once, it’s not just the dividend crowd paying attention. The stock may have fumbled the market’s mood on Halloween with a 4% drop, but don’t let that spook you – what’s lurking underneath is far more intriguing than the reactionary selling would suggest. The company beat […]
Mad Hedge Biotech and Healthcare Letter November 11, 2025 Fiat Lux Featured Trade: (A WELL-OILED MACHINE) (JNJ)
If you’ve ever doubted that a 137-year-old blue-chip beast could still surprise Wall Street, take a look at Johnson & Johnson’s (JNJ) recent maneuvering. The company just turned in a surprisingly robust Q3 performance, with $24 billion in revenue and a raised full-year forecast. But forget the top-line cheerleading. What I’m watching is where this […]
Mad Hedge Biotech and Healthcare Letter November 6, 2025 Fiat Lux Featured Trade: (BLOOD SIMPLE) (GH)
At a biotech conference in San Francisco a few years ago, I found myself seated next to a young, eager analyst from a mid-tier hedge fund. He asked me if I thought liquid biopsy was “a real thing” or just another Silicon Valley mirage. I told him to watch Guardant Health (GH). If they cracked […]
Mad Hedge Biotech and Healthcare Letter November 4, 2025 Fiat Lux Featured Trade: (THE LONG VIEW) (REGN), (SNY), (NVO), (LLY)
Ah, Regeneron (REGN). Once the golden child of ophthalmology, now the grizzled veteran of biotech, hobbling through a few Eylea-induced aches and pains. But here’s the punchline: this old dog is learning some new tricks. And Wall Street is finally starting to notice. After a year in the earnings penalty box, Regeneron just delivered a […]
Mad Hedge Biotech and Healthcare Letter October 30, 2025 Fiat Lux Featured Trade: (BEHIND EVERY BREAKTHROUGH DRUG IS A MASSACHUSETTS PHONE NUMBER) (TMO), (PFE), (MRNA)